Advertisement

Clinical Reviews in Allergy & Immunology

, Volume 34, Issue 1, pp 56–64 | Cite as

Rituximab in Treatment-Resistant Autoimmune Blistering Skin Disorders

  • Enno SchmidtEmail author
  • Eva-Bettina Bröcker
  • Matthias Goebeler
Article

Abstract

Autoimmune blistering diseases are associated with autoantibodies to desmosomal (pemphigus group) or hemidesmosomal proteins (autoimmune subepidermal blistering disorders) that are essential for the structural integrity of the epidermis and dermoepidermal junction. Treatment is usually based on systemic glucocorticosteroids, which are often combined with additional immunosuppressants such as azathioprine and mycophenolate mofetil or immunomodulators including dapsone, antibiotics, and intravenous immunoglobulins. These interventions are sometimes not sufficient to induce remission and/or may be associated with intolerable adverse events. In such situations, the anti-CD20 antibody rituximab has been successfully applied in recent years. Rituximab transitorily depletes CD20-positive B lymphocytes from the circulation. It has been employed in more than 1 million patients with CD20-positive non-Hodgkin’s lymphoma and severe side effects were only rarely observed. Subsequently, the B cell-modulating effect of rituximab has encouraged its use in a variety of autoimmune diseases, including more than 40 patients with pemphigus. In addition, a few patients with bullous pemphigoid, mucous membrane pemphigoid, and epidermolysis bullosa acquisita have received rituximab. In the majority of these patients, clinical remission was induced; however, serious adverse events were considerable higher compared to both patients with non-Hodgkin’s lymphoma or nonbullous autoimmune disorders like lupus erythematosus, dermatomyositis, and rheumatoid arthritis.

Keywords

Autoantibody B lymphocyte Bullous pemphigoid Epidermolysis bullosa acquisita MabThera™ Pemphigus Rituxan™ Therapy 

References

  1. 1.
    Schmidt E, Zillikens D (2000) Autoimmune and inherited subepidermal blistering diseases: advances in the clinic and the laboratory. Adv Dermatol 16:113–157PubMedGoogle Scholar
  2. 2.
    Stanley JR, Amagai M (2006) Pemphigus, bullous impetigo, and the staphylococcal scalded-skin syndrome. N Engl J Med 355:1800–1810PubMedCrossRefGoogle Scholar
  3. 3.
    Harman KE, Albert S, Black MM (2003) Guidelines for the management of pemphigus vulgaris. Br J Dermatol 149:926–937PubMedCrossRefGoogle Scholar
  4. 4.
    Goebeler M, Sitaru C, Zillikens D (2004) Bullous autoimmune disorders: therapy. J Dtsch Dermatol Ges 2:774–793PubMedCrossRefGoogle Scholar
  5. 5.
    Goebeler M, Zillikens D (2006) Bullous pemphigoid: diagnosis and management. Expert Review of Dermatology 1:401–411CrossRefGoogle Scholar
  6. 6.
    Cohen Y, Solal-Celigny P, Polliack A (2003) Rituximab therapy for follicular lymphoma: a comprehensive review of its efficacy as primary treatment, treatment for relapsed disease, re-treatment and maintenance. Haematologica 88:811–823PubMedGoogle Scholar
  7. 7.
    George JN, el-Harake MA, Raskob GE (1994) Chronic idiopathic thrombocytopenic purpura. N Engl J Med 331:1207–1211PubMedCrossRefGoogle Scholar
  8. 8.
    Isenberg DA (2006) B cell targeted therapies in autoimmune diseases. J Rheumatol Suppl 77:24–28PubMedGoogle Scholar
  9. 9.
    Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, Stevens RM, Shaw T (2004) Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 350:2572–2581PubMedCrossRefGoogle Scholar
  10. 10.
    Browning JL (2006) B cells move to centre stage: novel opportunities for autoimmune disease treatment. Nat Rev Drug Discov 5:564–576PubMedCrossRefGoogle Scholar
  11. 11.
    Anolik JH, Barnard J, Cappione A, Pugh-Bernard AE, Felgar RE, Looney RJ, Sanz I (2004) Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum 50:3580–3590PubMedCrossRefGoogle Scholar
  12. 12.
    Leandro MJ, Cambridge G, Ehrenstein MR, Edwards JC (2006) Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum 54:613–620PubMedCrossRefGoogle Scholar
  13. 13.
    Vugmeyster Y, Howell K (2005) Rituximab-mediated depletion of cynomolgus monkey B cells in vitro in different matrices: possible inhibitory effect of IgG. Int Immunopharmacol 4:1117–1124CrossRefGoogle Scholar
  14. 14.
    Anolik JH, Campbell D, Felgar RE, Young F, Sanz I, Rosenblatt J, Looney RJ (2003) The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum 48:455–459PubMedCrossRefGoogle Scholar
  15. 15.
    Janas E, Priest R, Wilde JI, White JH, Malhotra R (2005) Rituxan (anti-CD20 antibody)-induced translocation of CD20 into lipid rafts is crucial for calcium influx and apoptosis. Clin Exp Immunol 139:439–446PubMedCrossRefGoogle Scholar
  16. 16.
    Schmidt E, Obe K, Bröcker EB, Zillikens D (2000) Serum levels of autoantibodies to BP180 correlate with disease activity in patients with bullous pemphigoid. Arch Dermatol 136:174–178PubMedCrossRefGoogle Scholar
  17. 17.
    Sitaru C, Mihai S, Otto C, Chiriac MT, Hausser I, Dotterweich B, Saito H, Rose C, Ishiko A, Zillikens D (2005) Induction of dermal–epidermal separation in mice by passive transfer of antibodies specific to type VII collagen. J Clin Invest 115:870–878PubMedCrossRefGoogle Scholar
  18. 18.
    Leandro MJ, Edwards JC, Cambridge G (2002) Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann Rheum Dis 61:883–888PubMedCrossRefGoogle Scholar
  19. 19.
    Schmidt E, Hunzelmann N, Zillikens D, Broecker EB, Goebeler M (2006) Rituximab in refractory autoimmune bullous diseases. Clin Exp Dermatol 31:503–508PubMedCrossRefGoogle Scholar
  20. 20.
    Schmidt E, Seitz CS, Benoit S, Bröecker EB, Goebeler M (2007) Rituximab in autoimmune bullous diseases: mixed responses and adverse effects. Br J Dermatol 156:352–356PubMedCrossRefGoogle Scholar
  21. 21.
    Belgi AS, Azeez M, Hoyle C, Williams RE (2006) Response of pemphigus vulgaris to anti-CD20 antibody therapy (rituximab) may be delayed. Clin Exp Dermatol 31:143PubMedCrossRefGoogle Scholar
  22. 22.
    Kong HH, Prose NS, Ware RE, Hall RP 3rd (2005) Successful treatment of refractory childhood pemphigus vulgaris with anti-CD20 monoclonal antibody (rituximab). Pediatr Dermatol 22:461–464PubMedCrossRefGoogle Scholar
  23. 23.
    Ahmed AR, Spigelman Z, Cavacini LA, Posner MR (2006) Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med 355:1772–1779PubMedCrossRefGoogle Scholar
  24. 24.
    Borradori L, Lombardi T, Samson J, Girardet C, Saurat JH, Hugli A (2001) Anti-CD20 monoclonal antibody (rituximab) for refractory erosive stomatitis secondary to CD20(+) follicular lymphoma-associated paraneoplastic pemphigus. Arch Dermatol 137:269–272PubMedGoogle Scholar
  25. 25.
    Barnadas M, Roe E, Brunet S, Garcia P, Bergua P, Pimentel L, Puig L, Francia A, Garcia R, Gelpi C, Sierra J, Coll P, Alomar A (2006) Therapy of paraneoplastic pemphigus with rituximab: a case report and review of literature. J Eur Acad Dermatol Venereol 20:69–74PubMedCrossRefGoogle Scholar
  26. 26.
    Esposito M, Capriotti E, Giunta A, Bianchi L, Chimenti S (2006) Long-lasting remission of pemphigus vulgaris treated with rituximab. Acta Derm Venereol 86:87–89PubMedGoogle Scholar
  27. 27.
    Borel C, Launay F, Garrouste C, Astudillo L, Bazex J, Arlet P, Paul C, Viraben R, Sailler L (2006) Rituximab induced remission of pemphigus vulgaris: 2 cases. Rev Med Interne 28:266–268PubMedCrossRefGoogle Scholar
  28. 28.
    Niedermeier A, Worl P, Barth S, Schuler G, Hertl M (2006) Delayed response of oral pemphigus vulgaris to rituximab treatment. Eur J Dermatol 16:266–270PubMedGoogle Scholar
  29. 29.
    McGinness JL, Bivens MM, Greer KE, Patterson JW, Saulsbury FT (2006) Immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) associated with pemphigoid nodularis: a case report and review of the literature. J Am Acad Dermatol 55:143–148PubMedCrossRefGoogle Scholar
  30. 30.
    Sadler E, Schafleitner B, Lanschuetzer C, Laimer M, Pohla-Gubo G, Hametner R, Hintner H, Bauer JW (2007) Treatment-resistant classical epidermolysis bullosa acquisita responding to rituximab. Br J Dermatol 157:417–419PubMedCrossRefGoogle Scholar
  31. 31.
    Goebeler M, Herzog S, Bröcker EB, Zillikens D (2003) Rapid response of treatment-resistant pemphigus foliaceus to the anti-CD20 antibody rituximab. Br J Dermatol 149:899–901PubMedCrossRefGoogle Scholar
  32. 32.
    Arin MP, Engert A, Krieg T, Hunzelmann N (2005) Anti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus. Br J Dermatol 153:620–625PubMedCrossRefGoogle Scholar
  33. 33.
    Szabolcs P, Reese M, Yancey KB, Hall RP, Kurtzberg J (2002) Combination treatment of bullous pemphigoid with anti-CD20 and anti-CD25 antibodies in a patient with chronic graft-versus-host disease. Bone Marrow Transplant 30:327–329PubMedCrossRefGoogle Scholar
  34. 34.
    Schmidt E, Benoit S, Bröcker EB, Zillikens D, Goebeler M (2006) Successful adjuvant treatment of recalcitrant epidermolysis bullosa acquisita with anti-CD20 antibody rituximab. Arch Dermatol 142:147–150PubMedCrossRefGoogle Scholar
  35. 35.
    Cambridge G, Leandro MJ, Teodorescu M, Manson J, Rahman A, Isenberg DA, Edwards JC (2006) B cell depletion therapy in systemic lupus erythematosus: effect on autoantibody and antimicrobial antibody profiles. Arthritis Rheum 54:3612–3622PubMedCrossRefGoogle Scholar
  36. 36.
    Dupuy A, Viguier M, Bedane C, Cordoliani F, Blaise S, Aucouturier F, Bonnetblanc JM, Morel P, Dubertret L, Bachelez H (2004) Treatment of refractory pemphigus vulgaris with rituximab (anti-CD20 monoclonal antibody). Arch Dermatol 140:91–96PubMedCrossRefGoogle Scholar
  37. 37.
    Schmidt E, Herzog S, Bröcker EB, Zillikens D, Goebeler M (2005) Long-standing remission of recalcitrant juvenile pemphigus vulgaris after adjuvant therapy with rituximab. Br J Dermatol 153:449–451PubMedCrossRefGoogle Scholar
  38. 38.
    Radbruch A, Muehlinghaus G, Luger EO, Inamine A, Smith KG, Dorner T, Hiepe F (2006) Competence and competition: the challenge of becoming a long-lived plasma cell. Nat Rev Immunol 6:741–750PubMedCrossRefGoogle Scholar
  39. 39.
    Looney RJ, Anolik JH, Campbell D, Felgar RE, Young F, Arend LJ, Sloand JA, Rosenblatt J, Sanz I (2004) B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 50:2580–2589PubMedCrossRefGoogle Scholar
  40. 40.
    Levine TD (2005) Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum 52:601–607PubMedCrossRefGoogle Scholar
  41. 41.
    Willems M, Haddad E, Niaudet P, Kone-Paut I, Bensman A, Cochat P, Deschenes G, Fakhouri F, Leblanc T, Llanas B, Loirat C, Pillet P, Ranchin B, Salomon R, Ulinski T, Bader-Meunier B (2006) Rituximab therapy for childhood-onset systemic lupus erythematosus. J Pediatr 148:623–627PubMedCrossRefGoogle Scholar
  42. 42.
    Quartier P, Brethon B, Philippet P, Landman-Parker J, Le Deist F, Fischer A (2001) Treatment of childhood autoimmune haemolytic anaemia with rituximab. Lancet 358:1511–1513PubMedCrossRefGoogle Scholar
  43. 43.
    Zecca M, Nobili B, Ramenghi U, Perrotta S, Amendola G, Rosito P, Jankovic M, Pierani P, De Stefano P, Bonora MR, Locatelli F (2003) Rituximab for the treatment of refractory autoimmune hemolytic anemia in children. Blood 101:3857–3861PubMedCrossRefGoogle Scholar
  44. 44.
    Bennett CM, Rogers ZR, Kinnamon DD, Bussel JB, Mahoney DH, Abshire TC, Sawaf H, Moore TB, Loh ML, Glader BE, McCarthy MC, Mueller BU, Olson TA, Lorenzana AN, Mentzer WC, Buchanan GR, Feldman HA, Neufeld EJ (2006) Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura. Blood 107:2639–2642PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc. 2007

Authors and Affiliations

  • Enno Schmidt
    • 1
    Email author
  • Eva-Bettina Bröcker
    • 1
  • Matthias Goebeler
    • 2
  1. 1.Department of DermatologyUniversity of WürzburgWürzburgGermany
  2. 2.Department of DermatologyUniversity of Heidelberg, University Medical Center MannheimMannheimGermany

Personalised recommendations